Despite the great efficacy of currently commercialized ADCs for HER-2-overexpressing breast cancer, mechanisms of resistance to T-DM1 and T-DXd have already been identified, and the development of further ADCs, with a greater therapeutic index and less toxicity, is needed, justifying continued research in this area. This evidence concerns the gene ERBB2 and breast carcinoma.